share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  05/22 05:16
牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has announced that it is facing delisting from The Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement. The company was initially notified by Nasdaq on November 15, 2023, and was given until May 13, 2024, to regain compliance. Failing to meet the requirement, the company received a delisting determination letter on May 14, 2024, with a suspension of trading set to commence on May 23, 2024. However, 180 Life Sciences has appealed the decision, and the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel. The company plans to present a compliance plan at the Panel hearing. In the meantime, trading of the company's common stock and public warrants will continue on Nasdaq under the...Show More
180 Life Sciences Corp. has announced that it is facing delisting from The Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement. The company was initially notified by Nasdaq on November 15, 2023, and was given until May 13, 2024, to regain compliance. Failing to meet the requirement, the company received a delisting determination letter on May 14, 2024, with a suspension of trading set to commence on May 23, 2024. However, 180 Life Sciences has appealed the decision, and the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel. The company plans to present a compliance plan at the Panel hearing. In the meantime, trading of the company's common stock and public warrants will continue on Nasdaq under the symbols 'ATNF' and 'ATNFW'. The company acknowledges that there is no assurance that its plan will be accepted or that it will be able to regain compliance with Nasdaq's listing requirements. The potential delisting could negatively impact the company's stock and warrant prices, its ability to raise capital, and could trigger defaults and penalties under existing agreements.
180 生命科學公司宣佈，由於不遵守最低股東權益要求，它正面臨從納斯達克股票市場退市。納斯達克最初於2023年11月15日通知該公司，並獲准在2024年5月13日之前恢復合規。由於未能滿足要求，該公司於2024年5月14日收到退市決定書，暫停交易定於2024年5月23日開始。但是，180 Life Sciences已對該決定提出上訴，除名行動已暫停，等待納斯達克聽證小組的最終決定。該公司計劃在小組聽證會上提交合規計劃。同時，該公司的普通股和公開認股權證將繼續在納斯達克交易，交易代碼爲 “ATNF” 和 “ATNFW”。該公司承認，無法保證其計劃會被接受，也無法保證其能夠重新遵守納斯達克的上市要求。潛在的退市可能會對公司的股票和權證價格及其籌集資金的能力產生負面影響，並可能觸發現有協議規定的違約和處罰。
180 生命科學公司宣佈，由於不遵守最低股東權益要求，它正面臨從納斯達克股票市場退市。納斯達克最初於2023年11月15日通知該公司，並獲准在2024年5月13日之前恢復合規。由於未能滿足要求，該公司於2024年5月14日收到退市決定書，暫停交易定於2024年5月23日開始。但是，180 Life Sciences已對該決定提出上訴，除名行動已暫停，等待納斯達克聽證小組的最終決定。該公司計劃在小組聽證會上提交合規計劃。同時，該公司的普通股和公開認股權證將繼續在納斯達克交易，交易代碼爲 “ATNF” 和 “ATNFW”。該公司承認，無法保證其計劃會被接受，也無法保證其能夠重新遵守納斯達克的上市要求。潛在的退市可能會對公司的股票和權證價格及其籌集資金的能力產生負面影響，並可能觸發現有協議規定的違約和處罰。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。